229 related articles for article (PubMed ID: 15688032)
1. The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP.
Dennler S; Pendaries V; Tacheau C; Costas MA; Mauviel A; Verrecchia F
Oncogene; 2005 Mar; 24(11):1936-45. PubMed ID: 15688032
[TBL] [Abstract][Full Text] [Related]
2. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators.
Ghosh AK; Yuan W; Mori Y; Varga J
Oncogene; 2000 Jul; 19(31):3546-55. PubMed ID: 10918613
[TBL] [Abstract][Full Text] [Related]
3. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1.
Jinnin M; Ihn H; Asano Y; Yamane K; Trojanowska M; Tamaki K
Oncogene; 2004 Mar; 23(9):1656-67. PubMed ID: 15001984
[TBL] [Abstract][Full Text] [Related]
4. Cited2 modulates TGF-beta-mediated upregulation of MMP9.
Chou YT; Wang H; Chen Y; Danielpour D; Yang YC
Oncogene; 2006 Sep; 25(40):5547-60. PubMed ID: 16619037
[TBL] [Abstract][Full Text] [Related]
5. Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1.
Liu C; Lu J; Tan J; Li L; Huang B
Cytokine; 2004 Aug 21-Sep 7; 27(4-5):93-100. PubMed ID: 15271374
[TBL] [Abstract][Full Text] [Related]
6. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
Suh N; Roberts AB; Birkey Reffey S; Miyazono K; Itoh S; ten Dijke P; Heiss EH; Place AE; Risingsong R; Williams CR; Honda T; Gribble GW; Sporn MB
Cancer Res; 2003 Mar; 63(6):1371-6. PubMed ID: 12649201
[TBL] [Abstract][Full Text] [Related]
7. Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism.
Schiller M; Verrecchia F; Mauviel A
Oncogene; 2003 Dec; 22(55):8881-90. PubMed ID: 14654784
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
Bhattacharyya S; Ghosh AK; Pannu J; Mori Y; Takagawa S; Chen G; Trojanowska M; Gilliam AC; Varga J
Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
[TBL] [Abstract][Full Text] [Related]
9. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB.
Nagarajan RP; Chen F; Li W; Vig E; Harrington MA; Nakshatri H; Chen Y
Biochem J; 2000 Jun; 348 Pt 3(Pt 3):591-6. PubMed ID: 10839991
[TBL] [Abstract][Full Text] [Related]
10. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner.
Pendaries V; Verrecchia F; Michel S; Mauviel A
Oncogene; 2003 Nov; 22(50):8212-20. PubMed ID: 14603262
[TBL] [Abstract][Full Text] [Related]
12. Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation.
Verrecchia F; Tacheau C; Schorpp-Kistner M; Angel P; Mauviel A
Oncogene; 2001 Apr; 20(18):2205-11. PubMed ID: 11402315
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP.
Cui Q; Lim SK; Zhao B; Hoffmann FM
Oncogene; 2005 Jun; 24(24):3864-74. PubMed ID: 15750622
[TBL] [Abstract][Full Text] [Related]
14. A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction.
Kim RH; Wang D; Tsang M; Martin J; Huff C; de Caestecker MP; Parks WT; Meng X; Lechleider RJ; Wang T; Roberts AB
Genes Dev; 2000 Jul; 14(13):1605-16. PubMed ID: 10887155
[TBL] [Abstract][Full Text] [Related]
15. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation.
Gu L; Zhu YJ; Yang X; Guo ZJ; Xu WB; Tian XL
Acta Pharmacol Sin; 2007 Mar; 28(3):382-91. PubMed ID: 17303001
[TBL] [Abstract][Full Text] [Related]
16. Smad3 is acetylated by p300/CBP to regulate its transactivation activity.
Inoue Y; Itoh Y; Abe K; Okamoto T; Daitoku H; Fukamizu A; Onozaki K; Hayashi H
Oncogene; 2007 Jan; 26(4):500-8. PubMed ID: 16862174
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability.
Zhu S; Goldschmidt-Clermont PJ; Dong C
Circ Res; 2004 Mar; 94(5):617-25. PubMed ID: 14739161
[TBL] [Abstract][Full Text] [Related]
18. Roles for lysine residues of the MH2 domain of Smad3 in transforming growth factor-beta signaling.
Imoto S; Sugiyama K; Sekine Y; Matsuda T
FEBS Lett; 2005 May; 579(13):2853-62. PubMed ID: 15907489
[TBL] [Abstract][Full Text] [Related]
19. Repression of Smad-dependent transforming growth factor-beta signaling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB.
Mori N; Morishita M; Tsukazaki T; Yamamoto N
Int J Cancer; 2003 Jul; 105(5):661-8. PubMed ID: 12740915
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.
Javelaud D; Mauviel A
Oncogene; 2005 Aug; 24(37):5742-50. PubMed ID: 16123807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
